Medical Condition News

RSS

Researchers discover CD19 pathway that leads to lymphoma

Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma.

8 May 2012

Declining biodiversity may contribute to rise in asthma, allergies

Declining biodiversity may be contributing to the rise of asthma, allergies, and other chronic inflammatory diseases among people living in cities worldwide, a Finnish study suggests. Emerging evidence indicates that commensal microbes inhabiting the skin, airway, and gut protect against inflammatory disorders. However, little is known about the environmental determinants of the microbiome.

8 May 2012

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting.

8 May 2012

Zinc oxide could increase risk of skin cancer

As vacationers prepare to spend time outdoors this summer, many of them will pack plenty of sunscreen in hopes it will protect their bodies from overexposure, and possibly from skin cancer. But researchers at Missouri University of Science and Technology are discovering that sunscreen may not be so safe after all.

8 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Specific proteins can help identify patients with IBS

Irritable bowel syndrome (IBS) is hard to diagnose as well as treat, but researchers at the Sahlgrenska Academy, at the University of Gothenburg, Sweden, have discovered a way of confirming the disorder using stool samples.

8 May 2012

Health Canada announces labelling update for Cipralex

Health Canada is informing Canadians of a labelling update for the prescription drug Cipralex (the brand name of the drug escitalopram) regarding a dose-related risk of abnormal heart rhythms. Cipralex is used to treat depression and belongs to a family of drugs known as Selective Serotonin Reuptake Inhibitors (SSRIs).

7 May 2012

New instrument to measure Facebook addiction

Are you a social media enthusiast or simply a Facebook addict? Researchers from Norway have developed a new instrument to measure Facebook addiction, the Bergen Facebook Addiction Scale.

7 May 2012

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.

7 May 2012

Impairment of daily rhythms has multiple adverse effects on human health

If you're counting calories to lose weight, that may be only part of the weight loss equation says a new research report published online in The FASEB Journal.

7 May 2012

Positive long-term outcome data for chronic ITP patients treated with rituxamab

A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).

7 May 2012

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies.

7 May 2012

TOKU-E introduces faster dissolving dust-free grade Sodium Dodecyl Sulfate

TOKU-E Company has announced availability of their newly developed, innovative, ultra-safe, faster dissolving dust-free grade (DF) Sodium Dodecyl Sulfate (SDS).

7 May 2012

CardioKinetix Parachute Ventricular Partitioning Device trial data presented at 2012 EuroPCR

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that clinical trial data from the first-of-its-kind Parachute Ventricular Partitioning Device for the treatment of patients with ischemic heart failure will be presented at the 2012 EuroPCR Conference in Paris.

7 May 2012

Positive results from PROLOR Biotech's hGH-CTP Phase II trial for growth hormone deficiency

PROLOR Biotech, Inc. today reported top-line results from a Phase II four-month treatment extension study of hGH-CTP, its long-acting version of human growth hormone, in growth hormone deficient adults.

7 May 2012

Galleon GAL-021 safe and well-tolerated in Phase I respiratory depression clinical study

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing disorders, today announced that its investigational drug GAL-021 appeared to be safe and well-tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase I clinical study of 30 healthy adults.

7 May 2012

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs).

7 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

KYTHERA ATX-101-10-16 trial for submental fat meets primary endpoints

KYTHERA Biopharmaceuticals, Inc. today announced the presentation of initial trial results from Study ATX-101-10-16, the first of two pivotal European Phase III clinical trials with ATX-101, a facial injectable drug for the reduction of unwanted fat under the chin, or submental fat.

7 May 2012

Screening for diabetic retinopathy once every two years maybe safe, cost-effective

Research carried out at the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, has concluded that it would be a safe and cost-effective strategy to screen people with type 2 diabetes who have not yet developed diabetic retinopathy, for the disease once every two years instead of annually.

7 May 2012

Medical Condition News

Researchers discover CD19 pathway that leads to lymphoma

Declining biodiversity may contribute to rise in asthma, allergies

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

Zinc oxide could increase risk of skin cancer

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Specific proteins can help identify patients with IBS

Health Canada announces labelling update for Cipralex

New instrument to measure Facebook addiction

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Impairment of daily rhythms has multiple adverse effects on human health

Positive long-term outcome data for chronic ITP patients treated with rituxamab

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

TOKU-E introduces faster dissolving dust-free grade Sodium Dodecyl Sulfate

CardioKinetix Parachute Ventricular Partitioning Device trial data presented at 2012 EuroPCR

Positive results from PROLOR Biotech's hGH-CTP Phase II trial for growth hormone deficiency

Galleon GAL-021 safe and well-tolerated in Phase I respiratory depression clinical study

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

KYTHERA ATX-101-10-16 trial for submental fat meets primary endpoints

Screening for diabetic retinopathy once every two years maybe safe, cost-effective

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News